Castle Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CSTL and other ETFs, options, and stocks.About CSTL
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma.
CEODerek J. Maetzold
CEODerek J. Maetzold
Employees761
Employees761
HeadquartersFriendswood, Texas
HeadquartersFriendswood, Texas
Founded2007
Founded2007
Employees761
Employees761
CSTL Key Statistics
Market cap1.23B
Market cap1.23B
Price-Earnings ratio-89.31
Price-Earnings ratio-89.31
Dividend yield—
Dividend yield—
Average volume403.07K
Average volume403.07K
High today$41.14
High today$41.14
Low today$40.01
Low today$40.01
Open price$41.05
Open price$41.05
Volume225.51K
Volume225.51K
52 Week high$42.18
52 Week high$42.18
52 Week low$14.59
52 Week low$14.59
Stock Snapshot
As of today, Castle Biosciences(CSTL) shares are valued at $40.10. The company's market cap stands at 1.23B, with a P/E ratio of -89.31.
On 2025-12-24, Castle Biosciences(CSTL) stock traded between a low of $40.01 and a high of $41.14. Shares are currently priced at $40.10, which is +0.2% above the low and -2.5% below the high.
The Castle Biosciences(CSTL)'s current trading volume is 225.51K, compared to an average daily volume of 403.07K.
In the last year, Castle Biosciences(CSTL) shares hit a 52-week high of $42.18 and a 52-week low of $14.59.
In the last year, Castle Biosciences(CSTL) shares hit a 52-week high of $42.18 and a 52-week low of $14.59.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CSTL. This list is generated using Robinhood data, and it’s not a recommendation.